These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18054209

  • 21. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.
    Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F.
    Lancet; 1997 May 31; 349(9065):1594-7. PubMed ID: 9174562
    [Abstract] [Full Text] [Related]

  • 22. A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.
    Martiny K, Lunde M, Bech P, Plenge P.
    Nord J Psychiatry; 2012 Jun 31; 66(3):147-54. PubMed ID: 22458638
    [Abstract] [Full Text] [Related]

  • 23. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.
    J Clin Psychiatry; 2006 Feb 31; 67(2):288-96. PubMed ID: 16566626
    [Abstract] [Full Text] [Related]

  • 24. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression.
    Segrave R, Nathan PJ.
    Hum Psychopharmacol; 2005 Apr 31; 20(3):163-74. PubMed ID: 15648095
    [Abstract] [Full Text] [Related]

  • 25. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials.
    Ballesteros J, Callado LF.
    J Affect Disord; 2004 Apr 31; 79(1-3):137-47. PubMed ID: 15023488
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pindolol and the acceleration of the antidepressant response.
    Plenge P, Mellerup ET.
    J Affect Disord; 2003 Aug 31; 75(3):285-9. PubMed ID: 12880941
    [Abstract] [Full Text] [Related]

  • 28. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
    Blier P, Bergeron R, de Montigny C.
    Neuropsychopharmacology; 1997 May 31; 16(5):333-8. PubMed ID: 9109104
    [Abstract] [Full Text] [Related]

  • 29. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.
    Stein MB, Sareen J, Hami S, Chao J.
    Am J Psychiatry; 2001 Oct 31; 158(10):1725-7. PubMed ID: 11579011
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.
    Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP.
    J Am Acad Child Adolesc Psychiatry; 2001 Jul 31; 40(7):762-72. PubMed ID: 11437014
    [Abstract] [Full Text] [Related]

  • 31. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K, Perry CM.
    CNS Drugs; 2001 Jul 31; 15(8):643-69. PubMed ID: 11524036
    [Abstract] [Full Text] [Related]

  • 32. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.
    Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD.
    Am J Psychiatry; 2001 Jun 31; 158(6):906-12. PubMed ID: 11384898
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The use of pindolol to potentiate antidepressant medication.
    Blier P, Bergeron R.
    J Clin Psychiatry; 1998 Jun 31; 59 Suppl 5():16-23; discussion 24-5. PubMed ID: 9635544
    [Abstract] [Full Text] [Related]

  • 35. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.
    J Clin Psychopharmacol; 2008 Dec 31; 28(6):631-7. PubMed ID: 19011431
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME.
    J Affect Disord; 2000 Aug 31; 59(2):119-26. PubMed ID: 10837880
    [Abstract] [Full Text] [Related]

  • 38. Once-daily high-dose pindolol for SSRI-refractory depression.
    Sokolski KN, Conney JC, Brown BJ, DeMet EM.
    Psychiatry Res; 2004 Feb 15; 125(2):81-6. PubMed ID: 15006431
    [Abstract] [Full Text] [Related]

  • 39. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
    Kasper S, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2005 Aug 15; 21(8):1139-46. PubMed ID: 16083521
    [Abstract] [Full Text] [Related]

  • 40. Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine.
    Chiu HJ, Hong CJ, Chan CH.
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Jun 15; 57(6):418-23. PubMed ID: 8803304
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.